We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Potential Biomarker Determines Risk of Type 2 Diabetes

By LabMedica International staff writers
Posted on 08 Oct 2013
A definitive link has been discovered between certain lifestyle and demographic factors and a potential biomarker to determine the risk of type 2 diabetes.

The biomarker is a protein called sex hormone binding globulin (SHBG) and low levels can be an indication of increased risk for metabolic syndrome and type 2 diabetes years in advance.

Scientists at Brown University (Providence, RI, USA) measured the levels of SHBG in 13,547 women who were a part of the national Women's Health Initiative. More...
Although the team had found that SHBG levels are able to predict the risk of type 2 diabetes, and that several mutations in the genetic coding for the protein are also predictive factors, they say this study shows protein does not necessarily remain unchanged throughout the lifetime of the individual.

Plasma SHBG concentrations were measured using an electrochemiluminescence immunoassay (Roche Diagnostics; Indianapolis, IN, USA), a solid-phase two-site chemiluminescent immunoassay (Siemens Healthcare Diagnostics; Malvern, PA, USA), or an immunoradiometric assay (Esoterix Laboratory Services; Austin, TX, USA).

In the analysis of the results, the scientists found that age, use of estrogen replacement therapy, physical activity, and coffee consumption were significantly higher in women with higher SHBG levels. However, women with a high body mass index (BMI) were linked to low SHBG levels, but the significant associations of SHBG in women did not vary between ethnic groups. The results of the study could also lead to potential new interventions, as BMI, physical activity, estrogen therapy and coffee intake can all be adjusted. The authors noted that by knowing these factors are linked to the biomarker, this suggests changing these elements of lifestyle could, in turn, adjust levels of protein over time, therefore affecting the risk of diabetes.

Simin Liu, MD, ScD, a professor of medicine at Brown, and the senior author of the study said, “This protein seems to capture the cumulative effect between the gene and our environment in reflecting a metabolic state of our body, particularly in the liver, ultimately affecting diabetes risk. By the time you are checking blood glucose it's too late, because you use that as a diagnostic criterion to define diabetes. Our argument is that you can go to the doctor's office and check this protein that can predict your future risk 6 to 10 years down the line." The study was published on September 18, 2013, in the journal Clinical Chemistry.

Related Links:

Brown University
Roche Diagnostics
Siemens Healthcare Diagnostics




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.